CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Dova Pharmaceuticals, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Dova Pharmaceuticals, Inc.
240 Leigh Farm Road
Phone: (919) 806-4487p:919 806-4487 Durham, NC  27707-8100  United States Fax: (302) 636-5454f:302 636-5454
This company was Merged or Acquired on 11/10/2019.
This company ceased filing statements with the SEC on 11/22/2019.
This is a Subsidiary, click here for the Parent Company
Business Summary
Dova Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD). The Company’s product candidate, avatrombopag is an orally administered thrombopoietin receptor agonist, or TPO-RA. The Company has completed pivotal Phase 3 clinical trials that evaluated avatrombopag for the treatment of thrombocytopenia in patients with CLD. The Company has not generated any revenue.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/201912/31/2018YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer and Director AlexSapir
Chief Executive Officer TorbjomHallberg 11/12/2019 11/12/2019
Chief Financial Officer DouglasBlankenship
6 additional Officers and Directors records available in full report.

Business Names
Business Name
AkaRx, Inc
AkaRX, Inc.
DOVA
Dova Pharmaceuticals Ireland Limited

General Information
Number of Employees: 115 (As of 2/28/2019)
Outstanding Shares: 28,821,405 (As of 9/30/2019)
Shareholders: 12
Stock Exchange: NASD
Federal Tax Id: 813858961
Fax Number: (302) 636-5454


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023